Analyzing the chemical space coverage in commercial fragment screening collections revealed the overlap between bioactive medicinal chemistry substructures and rule-of-three compliant fragments is only ∼25%. We recommend including these fragments in fragment screening libraries to maximize confidence in discovering hit matter within known bioactive chemical space, while incorporation of nonoverlapping substructures could offer novel hits in screening libraries. Using principal component analysis, polar and three-dimensional substructures display a higher-than-average enrichment of bioactive compounds, indicating increasing representation of these substructures may be beneficial in fragment screening
Fragment-based approaches have now become an important component of the drug discovery process. At t...
The screening of a reduced yet diverse and synthesizable region of the chemical space is a critical ...
Fragment screening is the process of identifying relatively simple, often weakly potent
*S Supporting Information ABSTRACT: Analyzing the chemical space coverage in commercial fragment scr...
Most libraries for fragment-based drug discovery are restricted to 1,000-10,000 compounds, but over ...
*S Supporting Information ABSTRACT: Most libraries for fragment-based drug discov-ery are restricted...
Most libraries for fragment-based drug discovery are restricted to 1,000–10,000 compounds, but over ...
Natural products are universally recognized to contribute valuable chemical diversity to the design ...
We introduce a novel strategy to sample the bioactive chemical space, which follows up on hits from ...
Natural products are universally recognized to contribute valuable chemical diversity to the design ...
The generation of novel bioactive compounds based on existing lead series is a frequently occurring ...
Current fragment-based drug design relies on the efficient exploration of chemical space by using st...
Introduction in the 1990s of the concept of fragment screening opened up for a new era in drug disco...
Fragment-based drug design is an established strategy of finding new drugs. Instead of doing mass sc...
Screening against biochemical targets with compact chemical fragments has developed a reputation as ...
Fragment-based approaches have now become an important component of the drug discovery process. At t...
The screening of a reduced yet diverse and synthesizable region of the chemical space is a critical ...
Fragment screening is the process of identifying relatively simple, often weakly potent
*S Supporting Information ABSTRACT: Analyzing the chemical space coverage in commercial fragment scr...
Most libraries for fragment-based drug discovery are restricted to 1,000-10,000 compounds, but over ...
*S Supporting Information ABSTRACT: Most libraries for fragment-based drug discov-ery are restricted...
Most libraries for fragment-based drug discovery are restricted to 1,000–10,000 compounds, but over ...
Natural products are universally recognized to contribute valuable chemical diversity to the design ...
We introduce a novel strategy to sample the bioactive chemical space, which follows up on hits from ...
Natural products are universally recognized to contribute valuable chemical diversity to the design ...
The generation of novel bioactive compounds based on existing lead series is a frequently occurring ...
Current fragment-based drug design relies on the efficient exploration of chemical space by using st...
Introduction in the 1990s of the concept of fragment screening opened up for a new era in drug disco...
Fragment-based drug design is an established strategy of finding new drugs. Instead of doing mass sc...
Screening against biochemical targets with compact chemical fragments has developed a reputation as ...
Fragment-based approaches have now become an important component of the drug discovery process. At t...
The screening of a reduced yet diverse and synthesizable region of the chemical space is a critical ...
Fragment screening is the process of identifying relatively simple, often weakly potent